Condition: Metastatic Castration-resistant Prostate Cancer · Sponsor: Amgen
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| City of Hope Cancer Center Phoenix | Goodyear, Arizona, United States | Recruiting |
| City of Hope National Medical Center | Duarte, California, United States | Recruiting |
| City of Hope Orange County Lennar Foundation Cancer Center | Duarte, California, United States | Recruiting |
| Providence Saint Jude Medical Center | Fullerton, California, United States | Recruiting |
| University of California Irvine | Orange, California, United States | Recruiting |
| Providence Saint Johns Health Center | Santa Monica, California, United States | Recruiting |
| Rocky Mountain Cancer Centers | Denver, Colorado, United States | Recruiting |
| Hartford HealthCare Cancer Institute at Hartford Hospital | Hartford, Connecticut, United States | Recruiting |
| Medical Oncology Hematology Consultants Helen F Graham Cancer Center | Newark, Delaware, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| City of Hope Atlanta | Newnan, Georgia, United States | Recruiting |
| University of Illinois Chicago | Chicago, Illinois, United States | Recruiting |
+ 132 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07213674